Ranibizumab for Choroidal Neovascularization Secondary to Choroidal Osteoma Associated and Central Serous Choroidopathy 

Authors

  • Rosa Dolz-Marco Department of Ophthalmology, University and Polytechnic Hospital La Fe, Valencia, Spain
  • Sebastián Martínez-Castillo Department of Ophthalmology, University and Polytechnic Hospital La Fe, Valencia, Spain
  • Carol L. Shields Ocular Oncology Service, Wills Eye Institute, Thomas Jefferson University, Philadelphia, PA, USA
  • Roberto Gallego-Pinazo Department of Ophthalmology, University and Polytechnic Hospital La Fe, Valencia, Spain
  • Manuel Díaz-Llopis Department of Ophthalmology, University and Polytechnic Hospital La Fe, Valencia, Spain and Faculty of Medicine, University of Valencia, Valencia, Spain

DOI:

https://doi.org/10.12974/2309-6136.2013.01.01.9

Keywords:

Central Serous Choroidopathy, Choroidal Neovascularization, Choroidal Osteoma, Ranibizumab, Subretinal Fluid.

Abstract

Purpose: To describe a case of atypical choroidal osteoma with secondary choroidal neovascularization associated with chronic central serous chorioretinopathy.

Case Report: A 46-year-old man presented with a 6-month history of vision loss in his left eye (OS). The visual acuity was 20/30 in his OS. Dilated fundus examination OS evidenced a whitish deep lesion in the superior temporal arcade suggestive of choroidal osteoma. Spectral-domain optical coherence tomography revealed a serous macular detachment with a heterogeneous hyperreflective intrachoroidal mass within the superior temporal major arcade with overlying cystoid macular edema, and a temporal macular pigment epithelial detachment. An intravitreal injection of ranibizumab was administered and one month later the visual acuity improved to 20/25 and the subretinal fluid partially regressed. 

Conclusion: Although choroidal osteoma has no definite therapeutic approach, it may associate secondary complications. Patients should be monitored in order to detect changes suitable for potential therapies available and therefore minimize the visual burden of the disease. 

References

Gass JD, Guerry RK, Jack RL, Harris G. Choroidal osteoma. Arch Ophthalmol 1978; 96: 428-35. http://dx.doi.org/10.1001/archopht.1978.03910050204002

Rose SJ, Burke JF, Brockhurst RJ. Argon laser photoablation of a choroidal osteoma. Retina 1991; 11: 224-8. http://dx.doi.org/10.1097/00006982-199111020-00007

Hoffman ME, Sorr EM. Photocoagulation of subretinal neovascularization associated with choroidal osteoma. Arch Ophthalmol 1987; 105: 99-9. http://dx.doi.org/10.1001/archopht.1987.01060070142045

Singh AD, Talbot JF, Rundle PA, Rennie IG. Choroidal neovascularization secondary to choroidal osteoma: successful treatment with photodynamic therapy. Eye 2005; 19: 482-4. http://dx.doi.org/10.1038/sj.eye.6701475

Blaise P, Duchateau E, Comhaire Y, Rakic JM. Improvement of visual acuity after photodynamic therapy for choroidal neovascularization in choroidal osteoma. Acta Ophthalmol Scand 2005; 83: 515-6. http://dx.doi.org/10.1111/j.1600-0420.2005.00479.x

Sharma S, Sribhargava N, Shanmugam MP. Choroidal neovascular membrane associated with choroidal osteoma (CO) treated with trans-pupillary thermo therapy. Indian J Ophthalmol 2004; 52: 329-30.

Shukla D, Tanawade RG, Ramasamy K. Transpupillary thermotherapy for subfoveal choroidal neovascular membrane in choroidal osteoma. Eye 2006; 20: 845-7. http://dx.doi.org/10.1038/sj.eye.6702016

Ahmadieh H, Vafi N. Dramatic response of choroidal neovascularization associated with choroidal osteoma to the intravitreal injection of bevacizumab (Avastin). Graefes Arch Clin Exp Ophthalmol 2007; 245: 1731-3. http://dx.doi.org/10.1007/s00417-007-0636-z

Song WK, Koh HJ, Kwon OW, Byeon SH, Lee SC. Intravitreal bevacizumab for choroidal neovascularization secondary to choroidal osteoma. Acta Ophthalmol 2009; 87: 100-1. http://dx.doi.org/10.1111/j.1600-0420.2007.01136.x

Pandey N, Guruprasad A. Choroidal osteoma with choroidal neovascular membrane: successful treatment with intravitreal bevacizumab. Clin Ophthalmol 2010; 4: 1081-4. http://dx.doi.org/10.2147/OPTH.S13730

Song MH, Roh YJ. Intravitreal ranibizumab in a patient with choroidal neovascularization secondary to choroidal osteoma. Eye (Lond) 2009; 23: 1745-6. http://dx.doi.org/10.1038/eye.2008.313

HY Wu Z, YY Wong M, YY Lai T. Long-Term Follow-Up of Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization due to Choroidal Osteoma. Case Rep Ophthalmol 2012; 3: 200-4. http://dx.doi.org/10.1159/000339624

Shields CL, Sun H, Demirci H, Shields J. Factors predictive of tumor growth, tumor decalcification, choroidal neovascularization, and visual outcome in 74 eyes with choroidal osteoma. Arch Ophthalmol 2005; 123: 1658-66. http://dx.doi.org/10.1001/archopht.123.12.1658

Aylward GW, Chang TS, Pautler SE, Gass JD. A long-term follow-up of choroidal osteoma. Arch Ophthalmol 1998; 116: 1337-41. http://dx.doi.org/10.1001/archopht.116.10.1337

Lee YC, Sheu SJ. Choroidal osteoma masquerading as central serous chorioretinopathy. Kaohsiung J Med Sci 2002; 18: 408-11.

Song JH, Bae JH, Rho MI, Lee SC. Intravitreal bevacizumab in the management of subretinal fluid associated with choroidal osteoma. Retina 2010; 30: 945-51. http://dx.doi.org/10.1097/IAE.0b013e3181c720ca

Aylward GW, Chang TS, Pautler SE, Gass JD. A long-term follow-up of choroidal osteoma. Arch Ophthalmol 1998; 116: 1337-41. http://dx.doi.org/10.1001/archopht.116.10.1337

Sisk RA, Riemann CD, Petersen MR, Foster RE, Miller DM, Murray TG, Augsburger JJ. Fundus autofluorescence findings of choroidal osteoma. Retina 2013; 33(1): 97-104. http://dx.doi.org/10.1097/IAE.0b013e31825c1cde

Downloads

Published

2013-04-04

How to Cite

Dolz-Marco, R. ., Martínez-Castillo, S. ., Shields, C. L., Gallego-Pinazo, R. ., & Díaz-Llopis, M. . (2013). Ranibizumab for Choroidal Neovascularization Secondary to Choroidal Osteoma Associated and Central Serous Choroidopathy . Journal of Ocular Diseases and Therapeutics, 1(1), 41–44. https://doi.org/10.12974/2309-6136.2013.01.01.9

Issue

Section

Articles